GlaxoSmithKline plc (ADR) 

(Public, NYSE:GSK)   Watch this stock   
Find more results for GSK)
May 5, 2010
Annual General Meeting Add to calendar
Apr 27, 2010
Q1 2010 Earnings Release Add to calendar
Apr 27, 2010
Q1 2010 Earnings Conference Call Add to calendar
Feb 4, 2010
Q4 2009 Earnings Conference Call
Feb 4, 2010
Q4 2009 Earnings Release
Jan 12, 2010
JPMorgan Healthcare Conference
Dec 10, 2009
Business Briefing on Japan and Emerging Markets
More events from AOL Finance »    

Key stats and ratios

Q4 (Dec '09) 2009
Net profit margin 20.61% 19.98%
Operating margin 30.23% 29.69%
EBITD margin - 34.17%
Return on average assets 15.87% 13.78%
Return on average equity 67.80% 61.67%
Employees 99,003 -

Address

980 Great West Road Brentford
Middlesex, ENG TW8 9GS
United Kingdom - Map
+44-20-80475000 (Phone)
+44-20-80477807 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance

GlaxoSmithKline plc (ADR) discussions

  View all discussions »

Description

GlaxoSmithKline plc (GSK) is a global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. Its pharmaceutical products include medicines in the therapeutic areas, such as respiratory, central nervous system, anti-virals, anti-bacterials, metabolic, vaccines, cardiovascular and urogenital, oncology and emesis. It has operations in some 114 countries and products sold in over 150 countries. The Company operates in two segments: Pharmaceuticals (prescription pharmaceuticals and vaccines) and Consumer Healthcare. In July 2009, it acquired BMS' branded generics business, which comprises a portfolio of 13 branded pharmaceuticals. In July 2009, it acquired Stiefel Laboratories, Inc. In February 2010, the Company formed a new standalone unit specialising in the development and commercialisation of medicines for rare diseases.

Officers and directors

Andrew Philip Witty
Chief Executive Officer, Executive Director
Age: 44
Bio & Compensation - Reuters
Julian Spenser Heslop
Chief Financial Officer, Executive Director
Age: 55
Bio & Compensation - Reuters
Moncef Slaoui
Chairman - Research & Development, Executive Director
Age: 49
Bio & Compensation - Reuters
Marc Dunoyer
President, Pharmaceuticals Asia Pacific/Japan
Bio & Compensation - Reuters
David Pulman Ph.D.
President - Global Manufacturing and Supply
Bio & Compensation - Reuters
John Clarke
President - Consumer Healthcare
Bio & Compensation - Reuters
Eddie Gray
President, Pharmaceuticals Europe
Bio & Compensation - Reuters
Abbas Hussain
President - Emerging Markets
Bio & Compensation - Reuters
Roberto C. Taboada
President and Managing Director of Philippine Organization
Bio & Compensation - Reuters
Deirdre P. Connelly
President, North American Pharmaceuticals
Age: 48
Bio & Compensation - Reuters